I'm diligent about keeping up to date with many matters and I'm a regular reviewer so I would expect to pick up proposed changes to reference ranges among other matters.
There are some proposed changes to reference test ranges but one that springs to mind is one to challenge poor assumptions that are not grounded in plausible evidenced-based data:
Anaemia is associated with increased morbidity and mortality in patients undergoing anaesthesia; however, women are defined as being anaemic at a lower haemoglobin level than men. In this narrative review, we present the history of iron deficiency anaemia and how women’s health has often been overlooked.…We present data of population screening demonstrating how common iron deficiency is, affecting 12–18% of apparently ‘fit and healthy’ women, with the most common cause being heavy menstrual bleeding; both conditions being often unrecognised. We describe a range of symptoms reported by women, that vary from fatigue to brain fog, hair loss and eating ice…Overall, we demonstrate the need to single out women and investigate iron deficiency rather than accept the dogma of normality and differential treatment; this is to say, the need to change the current standard of care for women undergoing anaesthesia.
…
iron deficiency is so common in women that it can be regarded as ‘hiding in plain sight’, so much so that the original World Health Organization definition of anaemia, being a haemoglobin concentration < 120 g.l-1 in women compared with < 130 g.l-1 in men, was ‘arbitrary’ at best
…
Treatment of iron deficiency can improve skeletal muscle function and physical function, particularly in women, so if the target haemoglobin for optimal health is 140 g.l-1, then there is a need to single out women and investigate iron deficiency rather than accept the dogma of normality and differential treatment. Consideration of routine measurement of ferritin and haemoglobin in reproductive-aged women should be on the agenda of all healthcare provider systems.
Dugan, C., MacLean, B., Cabolis, K., Abeysiri, S., Khong, A., Sajic, M., Richards, T. and (2021), The misogyny of iron deficiency. Anaesthesia, 76: 56-62. doi.org/10.1111/anae.15432
Not related to reference ranges but I've seen that publications seem to confuse and heighten the risk of error rather than educate and contribute to patient safety. I'd originally seen the first line of this (mis)reported elsewhere but it wasn't until MedPage and reading the study that all became clear. (The risk of developing Type 2 diabetes is greater for transwomen than it is for women. However, as you might expect, the risk of transwomen developing Type 2 diabetes is is comparable to that for men.)
Diabetes Risk Higher for Transwomen vs Cisgender Females
— But risk wasn't any higher compared with cisgender men
…
Transwomen may face a higher risk for developing type 2 diabetes than cisgender women, a new study suggested.
Among those already diagnosed with type 2 diabetes at baseline, a total of 32% of transwomen were on gender-affirming hormone therapy, the group reported in the Journal of Clinical Endocrinology & Metabolism.
Transwomen also saw a 40% higher risk of developing incident type 2 diabetes during the average 3.1 years of follow-up compared with cisgender females (HR 1.4, 95% CI 1.1-1.8).
However, transwomen didn't have any excess risk for developing diabetes when compared with cisgender men (HR 1.2, 95% CI 0.9-1.5), which the researchers said "likely reflects the known gender disparity in [type 2 diabetes] risk in the general population."
And in an analysis restricted only to transgender and gender-diverse people receiving gender-affirming hormone therapy, transwomen didn't see a significantly higher prevalence of type 2 diabetes (OR 1.0, 95% 0.7-1.3) nor risk for incident diabetes (HR 1.4, 95% CI 0.8-2.4) versus cisgender females. This suggests that the excess diabetes risk for this population wasn't driven by hormonal therapy, the researchers said.
https://www.medpagetoday.com/endocrinology/diabetes/95937
Although transfeminine people may be at higher risk for T2DM compared with cisgender females, the corresponding difference relative to cisgender males is not discernable. Moreover, there is little evidence that T2DM occurrence in either transfeminine or transmasculine persons is attributable to GAHT use.
Study: Noreen Islam, Rebecca Nash, Qi Zhang, Leonidas Panagiotakopoulos, Tanicia Daley, Shalender Bhasin, Darios Getahun, J Sonya Haw, Courtney McCracken, Michael J Silverberg, Vin Tangpricha, Suma Vupputuri, Michael Goodman, Is There a Link Between Hormone Use and Diabetes Incidence in Transgender People? Data From the STRONG Cohort, The Journal of Clinical Endocrinology & Metabolism, Volume 107, Issue 4, April 2022, Pages e1549–e1557, https://doi.org/10.1210/clinem/dgab832
A long way to say, I'd be eager to rectify this vast hole in my knowledge about the (environmental? intentional?) impact of cross-sex hormones to which DU / BU refers.